Abstract.

Apigenin has special interest for the development of chemopreventive agents against cancer because it is a widely distributed plant flavonoid that has antitumor properties. In this study, we investigated the apigenin effects on the protease-mediated invasiveness in human metastatic cancer cell lines Caski, SK-Hep1, and MDA-231. We found that apigenin markedly inhibits the phorbol-12-myristate-13-acetate (PMA)-induced increase in MMP-9 expression and activity in several cancer cell lines. These effects of apigenin are dose-dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 5-fold induction in MMP-9 promoter activity, which was also suppressed by apigenin treatment in Caski cells. We found that apigenin could inhibit PMA-induced phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK), which was involved in the down-regulation of the expression of matrix metalloproteinase-9 (MMP-9) at mRNA levels. Furthermore, the treatment of inhibitors specific for p38 MAPK (SB203580) to Caski cells caused the reduction of MMP-9 expression. Restoration of p38 MAPK levels in Caski cells increased PMA-induced MMP-9 secretion blocked by apigenin treatment in Caski cells. These results indicated that apigenin might be a useful strategy for controlling metastasis and the invasiveness of tumors.

Introduction

Molecular mechanisms of tumor cell invasion and metastasis are complex processes involving action of extracellular matrix-degrading proteinase and migration through the ECM (1-3). Matrix metalloproteinases (MMPs) are enzymes involved in ECM degradation and play a crucial role in the process of cancer invasion and metastasis (4-6). Among human MMPs reported previously, gelatinase-A (MMP-2) and gelatinase-B (MMP-9) are key enzymes for degrading type IV collagen, which is a major component of the basement membrane (7,8). Expression levels of MMP-2 and MMP-9 are associated with tumor metastasis for various human cancers (9,10). Previous studies showed a positive correlation between expression of MMP-9 and tumor metastasis for colorectal cancer as well as several types of epithelial cancer (11,12); thus, inhibition of MMP activity has been adopted as an anticancer therapeutic strategy.

Apigenin is one of the flavonoids that is found in high amounts among several herbs and common fruits such as parsley, onions, oranges, tea, chamomile, thyme, and peppermint (13). Apigenin has gained particular interest in recent years as a beneficial and health promoting agent because of its low intrinsic toxicity and differential effects in normal versus cancer cells compared with other structurally related flavonoids (13). Apigenin inhibits motility and invasiveness of carcinoma cells in vitro, inhibitory mechanism(s) of apigenin on PMA-induced motility and invasiveness as well as PMA-induced MMP-9 activation of carcinoma cells is/are not well defined. The aim of this study was to evaluate the inhibitory effect of apigenin on PMA-promoting invasion as well as MMP-9 expression and activity in Caski cells. Furthermore, we determined whether the inhibition of these MMPs by apigenin treatment is mediated through the cellular signaling pathways such as by inhibition of the phosphorylation of p38 MAPK protein pathways of Caski cells.

Materials and methods

Cells and materials. Human Caski, SK-Hep-1, and MDA-231 cells were obtained from the American Type Culture Collection (Rockville, MD). The culture medium used throughout these experiments was Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% FBS. Apigenin
was purchased from Calbiochem (La Jolla, CA). Lipofectamine reagent was obtained from Life Technologies, Inc. (Rockville, MA). Luciferase assay and β-galactosidase assay systems were purchased from Promega (Madison, WI).

**Cell viability assay.** The effect of fisetin on cell viability was determined by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide] (MTT) assay. Cells were seeded into 96-well plates at a density of 3x10^4 cells/100 μl/well. After 24-h growth, cells were treated with different concentrations of apigenin ranging from 5 to 20 μM for 24 h. After the exposure period, medium was removed and the cells were washed with PBS. Then, the medium was changed and incubated with MTT solution (Promega, Southampton, UK) for 4 h. The number of viable cells was directly proportional to the production of formazan, which was then dissolved with DMSO, and measured spectrophotometrically at 563 nm. The percentage of viable cells was estimated by comparison with untreated control cells.

**Gelatin substrate gel zymography.** To determine the effect of apigenin on PMA-induced MMP-9 activity, cells were treated with various concentrations of apigenin in the presence of 75 nM PMA and then MMP-9 expression was evaluated by zymography. Zymography was performed by the procedure described by Overall et al (14) with minor modification. The human cell lines were suspended in their respective medium containing 10% fetal bovine serum and plated at 8x10^5 cells. Dishes were incubated until ~80% confluency, the medium was aspirated, and then fresh serum-free medium was added with or without apigenin. Supernatants were collected after incubation for 24 h. Supernatants were subjected to SDS-PAGE in 10% polyacrylamide gels that were copolymerized with 1 mg/ml of gelatin. After electrophoresis, the gels were washed several times in 2.5% Triton X-100 for 1 h at room temperature to remove the SDS, then incubated for 24-48 h at 37˚C in buffer containing 5 mM CaCl₂ and 1 μM ZnCl₂. The gels were stained with Coomassie blue (0.25%) for 30 min, and destained for 1 h in a solution of acetic acid and methanol. The proteolytic activity was evidenced as clear bands (zones of gelatin degradation) against the blue background of stained gelatin.

**Plasmids, transfection, and luciferase gene assays.** MMP-9 reporter construct were kindly provided by Dr T.K. Kwon (School of Medicine, Keimyung University, Korea). In brief, cells were seeded onto six-well plates at a density of 5x10^5 cells/well and grown overnight. Cells were transfected briefly, cells were seeded onto six-well plates at a density of ...

![Figure 1. Effects of various concentrations of apigenin on cell viability in cultured Caski cells. The proliferation of cell lines were quantified by the proliferation assay and luciferase gene assays. The proliferation of cell lines were quantified by the proliferation assay and luciferase gene assays.](image)

**Results**

**Effect of apigenin on the cell viability of cancer cells.** We checked the cell viability of various concentrations (0-20 μM) of apigenin on human cervical cancer Caski cells. Compared with that of controls, the remaining cell viability was not markedly altered by apigenin, even at a concentration up to 10 μM in Caski cells (Fig. 1). Therefore, it was clear that the...
treatment of apigenin, at concentrations ranging from 0 to 20 μM, has no cytotoxic effects to Caski cells for 24 h.

Effect of apigenin on MMP-9 activity. Caski cells, released basal levels of MMP-9 when cultured in serum-free medium, were treated with PMA for 24 h. Although the level of MMP-2 expression was not significantly altered by PMA, PMA induced the expression and secretion of large amounts of latent MMP-9 as determined by gelatin zymography (Fig. 2A). As shown in Fig. 2A, apigenin decreased PMA-induced MMP-9 activity in a dose-dependent manner, whereas the activity of a control metalloproteinase, of which the size was identical to the Mr 72,000 type IV collagenase MMP-2 (15), was not reduced in apigenin-treated cells.

Repression of PMA-induced MMP-9 transcription by apigenin. Treatment of Caski cells with apigenin also induced a decrease in the levels of PMA-stimulated MMP-9 mRNA (Fig. 2B). RT-PCR showed that steady-state MMP-9 mRNA levels were lower in apigenin-treated cells compared with non-treated cells. The effect of apigenin on MMP-9 expression was additionally investigated using HEK293 cells transiently transfected with a luciferase reporter gene linked to the 0.7-kb fragment of MMP-9 promoter sequence. As shown in Fig. 2C, luciferase gene expression was activated up to 5-fold in these cells treated with PMA compared with untreated cells. Treatment of cells with apigenin (5 μM) decreased PMA-mediated luciferase activity in a dose-dependent manner (Fig. 2C).

Effects of apigenin on the migration of Caski cells. We next examined the effect of apigenin on Caski cell invasion assay. As shown in Fig. 3, 5 μM apigenin reduced the PMA-induced invasiveness of these cells by ~50% compared with that of PMA-treated cells, although invasion was still reduced in the presence of apigenin. Therefore, the effect of apigenin on in vitro invasion inhibition was correlated with its effect on MMP-9 inhibition.

Apigenin inhibits PMA-induced secretion of MMP-9 and phosphorylation of p38 in Caski cells. In the next step, we examined the activation of the different mitogen-activated...
proteins kinase (MAPK) cascades by PMA and potential action of apigenin. We found that the phosphorylation of ERK appears after 30 min of PMA stimulation (Fig. 4A). PMA-induced ERK phosphorylation was partly inhibited by apigenin treatment, whereas apigenin on its own did not show any effect on the phosphorylation status of ERK. The treatment of Caski cells with PMA also increased the levels of phosphorylation of p38 compared with control after PMA stimulation, which was markedly attenuated by apigenin treatment. Although the treatment of Caski cells with PMA did not alter the levels of phosphorylation of JNK compared with control, apigenin alone showed the inhibitory effect on the phosphorylation status of JNK. Since PMA-induced p38 phosphorylation was strongly inhibited by apigenin, we checked whether apigenin plus p38 inhibitor SB203580 could additively down-regulate MMP-9 expression which is enhanced by PMA treatment at transcription level.

The combination treatment of SB203580 and apigenin inhibited MMP-9 activity and mRNA expression more compared with single treatment with SB203580 or apigenin (Fig. 4B). To evaluate whether the decreased PMA-induced MMP-9 secretion by apigenin was related to P38 signaling pathway, Caski cells were transiently transfected with empty vector and p38 expression vector. Treatment with apigenin in PMA-treated Caski cells that were transfected with empty vector led to decrease of MMP-9 secretion, which were slightly blocked by ectopic expression of p38 (Fig. 4C). This result indicated that the decrease in PMA-induced MMP-9 secretion by apigenin was related to the inhibition of p38 signaling pathway in Caski cells.
Collectively, apigenin inhibited PMA-induced secretion of MMP-9 and mRNA expression which was regulated at transcriptional level and PMA-prompting MMP-9 secretion via blocking p38 signaling pathway in Caski cells. In order to further investigate whether the inhibition of PMA-induced MMP-9 activation was mainly through the ERK or p38 MAPK signaling pathway, Caski cells were pretreated with a p38 inhibitor (SB203580; 20 μM) or ERK inhibitor (PD98059) for 1 h and then incubated with or without PMA for 24 h. The conditioned media were collected and MMP-2 and MMP-9 activities were determined by gelatin and casein zymography. These results indicated that the PMA-induced MMP-9 activity induced by PMA, respectively. These results indicated that the PMA-induced MMP-9 activation occurred through p38 or ERK activation in Caski cells.

Apigenin inhibits PMA-induced MMP-9 expression and activity in several metastatic cancer cells. We further investigated whether apigenin attenuates PMA-induced MMP-9 expression and activity in other human metastatic cancer cell types. As shown in Fig. 5A, apigenin did not markedly influence cell viability in MDA-231 and SK-Hep1 cells at concentration range from 5 to 20 μM. However, apigenin decreased PMA-induced MMP-9 activity in a dose-dependent manner in both cell lines (Fig. 5B). Furthermore, treatment of MDA-231 and SK-Hep1 cells with apigenin also induced a decrease in the levels of PMA-stimulated MMP-9 mRNA in a dose-dependent manner (Fig. 5C).

Discussion
Metastasis of cancer cells is a complex multistep process, which is regarded as the important biological characteristic of advanced and aggressive cancers (16). During the process of metastasis, the invasion and migration of cancer cells is the most important step. MMPs play a major role in promoting tumor metastasis, and overexpression of MMP-9 has been associated with the progression and invasion of tumors (4,17,18). Therefore, an agent that could efficiently
inhibit MMP-9 expression and activity would interfere with the invasion of the cancer cells thus giving therapeutic and/or adjuvant therapeutic effects against human metastatic cancer cells.

Recently, considerable attention has been devoted to identifying plant-derived dietary agents that interfere with tumor metastasis via inhibiting MMP-9 expression and activity because of their non-toxicity and biocompatibility (13,19-22). It has been reported that low-molecular-weight apigenin is useful in preventing tumor growth in many different types of human cancers (13,23,24). However, the precise actions of apigenin on the invasion and migration of human cancer cells including cervical, breast, and hepatoma cancer cells and the associated signaling pathways have not been reported. In this study, we found that apigenin suppressed PMA-enhanced MMP-9 secretion, mRNA, and transcriptional activity as well as PMA-induced invasion in cervical cancer cells.

Under standard culture conditions, Caski, MDA-231, and SK-Hep1 cells secreted a detectable level of MMP-9, which were up-regulated by PMA treatment. Our results show that apigenin, even though no effect on the expression level and basal secretion of MMP-9, totally abolished the response to PMA stimulation in those cancer cells. Our results are in agreement with the observations that apigenin blocked PMA-induced up-regulation of MMP-9 secretion in MDA-231 breast cancer cells (25). However, they reported that apigenin treatment caused a remarkable decrease at the mRNA and protein levels of urokinase plasminogen activator (u-PA), we failed to detect significant changes in u-PA mRNA expression level in Caski, MDA-231, and SK-Hep1 cell lines (data not shown). These results may reflect the importance of cell context in signal transduction pathways.

Several studies have identified signal transduction pathways such as ERK and p38 MAPK signaling pathways which were involved in regulation of MMP-2 and MMP-9 expression in malignant cells (25-28). In our system, PMA-induced MMP-9 expression was strongly attenuated by ERK inhibitor PD98059 or p38 inhibitor SB203580 treatment in Caski cells. In contrast, we failed to detect an increase of MMP-9 secretion blocked by apigenin treatment (Fig. 4C). These results suggested the possibility that apigenin might attenuate PMA-induced MMP-9 expression via p38-dependent pathways at transcriptional level.

Since a previous study demonstrated that dysregulation of the PI3K/Akt signaling pathway can lead to tumor progression (29), we checked whether apigenin treatment could inhibit PMA-induced Akt phosphorylation. Even though PMA did not activate Akt pathway in Caski cells, apigenin by itself suppressed the phosphorylated Akt levels (data not shown). Recently, it was reported that apigenin inhibited HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway in several cancer cells including MDA-MB-231, breast cancer cells, human hepatocellular carcinoma SKHepl cells and human lung carcinoma A549 cells (30). Our result and that of the previous study suggested the possibility that down-regulation of the PI3K/Akt signaling pathway by apigenin could be developed into cancer chemopreventor. We also showed that apigenin inhibits PMA-induced MMP-9 mRNA expression and its activity in MDA-231 and SK-Hep1 cells, suggesting that apigenin may commonly regulate MMP-9 induction by PMA at transcriptional levels in different cancer cells. Further investigations are needed to clarify the precise mechanism(s) by which apigenin affects PMA-induced MMP-9 transcriptional regulation.

In conclusion, we showed that apigenin inhibited PMA-induced invasion and metastasis by reducing MMP-9 expression and secretion and mainly through the p38 MAPK pathways in Caski human cervical cancer cells. In addition, the inhibitory effect on MMP-9 induction by apigenin was also found in MDA-231 human breast cancer cells and SK-Hep1 human hepatoma cells. As evidenced from the above results, apigenin has the potential to be a powerful candidate in developing preventive agents for cancer metastasis and this beneficial effect may expand future research on anticancer properties of apigenin in vitro and in vivo.

Acknowledgements

This study was supported by the Yeungnam University research grants in 2008.

References


